The Effect of Radiation Therapy on Tumor Immunity
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 139
- 试验地点
- 1
- 主要终点
- Outcome measures include changes in tumor-specific immune responses and general immune signature in patients undergoing Radiation Treatment. Reportable endpoints are absolute values of and changes in innate & adaptive immune cells and serum markers.
研究概览
简要总结
This research trial studies the effect of radiation therapy on tumor immunity. Standard radiation therapy destroys tumor cells. In response to tumor cell death caused by radiation therapy, the body has an ability to stimulate an anti-tumor response (immunity), but this response is often ineffective in shrinking tumor tissue. Collecting samples of blood from patients before, during, and after radiation therapy to study in the laboratory may help doctors learn more about the effects of radiation therapy on anti-tumor response.
详细描述
PRIMARY OBJECTIVES:
I. To assess the effect of radiation therapy on tumor immunity.
OUTLINE:
Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated Institutional Review Board (IRB)-approved Informed Consent form for the study
- •Received an explanation of the study, including satisfactory answers to all questions related to the proposed research
- •Is undergoing physician directed radiation treatment
排除标准
- •The potential Subject is unwilling or hesitant to participate for any reason and/or fails to complete the appropriate Informed Consent form
结局指标
主要结局
Outcome measures include changes in tumor-specific immune responses and general immune signature in patients undergoing Radiation Treatment. Reportable endpoints are absolute values of and changes in innate & adaptive immune cells and serum markers.
时间窗: The time line of interest covers a baseline, pre-treatment sample as well as mid-treatment and a post-treatment, follow-up sample at 3 months.
次要结局
未报告次要终点